TheraRadar
Data updated: Mar 29, 2026

CICLOPIROX

CICLOPIROX Protein Synthesis Inhibitors
Immunology Approved 1997-07-21

Ciclopirox Topical Solution, 8%, is indicated as a component of a comprehensive management program for the topical treatment of mild-to-moderate onychomycosis of the fingernails and toenails (without lunula involvement) in immunocompetent patients, specifically when caused by *Trichophyton rubrum*. The comprehensive management program requires the frequent removal (as often as monthly) of unattached, infected nails by a healthcare professional. The safety and efficacy of daily use beyond 48 weeks have not been established. It has not been studied in patients who are pregnant, nursing, immunocompromised, or those with insulin-dependent diabetes or diabetic neuropathy.

Source: FDA Label โ€ข PADAGIS ISRAEL

How CICLOPIROX Works

Ciclopirox is a broad-spectrum antifungal agent that operates through a unique mechanism compared to azoles or allylamines. It acts primarily by chelating polyvalent cations ($Fe^{3+}$ and $Al^{3+}$), which results in the inhibition of metal-dependent enzymes within the fungal cell, such as cytochromes, catalase, and peroxidase. These enzymes are essential for mitochondrial electron transport and the cellular degradation of peroxides. Furthermore, ciclopirox disrupts fungal cell membrane integrity by inhibiting the transport of essential nutrients (amino acids) and electrolytes, leading to fungal cell death.

19
Indications
--
Phase 3 Trials
28
Years on Market

CICLOPIROX Approval History

Loading approval history...

What CICLOPIROX Treats

1 indications

CICLOPIROX is approved for 1 conditions since its original approval in 1997. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Onychomycosis
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CICLOPIROX FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of n...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.